Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of the combination of truvada and
raltegravir given for 28 days for the prevention of HIV infection.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborators:
Gilead Sciences Merck Sharp & Dohme Corp.
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Raltegravir Potassium Tenofovir